Month: November 2022

Effect of food on the pharmacokinetics of omeprazole, pantoprazole and rabeprazole was written by Ochoa, Dolores;Roman, Manuel;Cabaleiro, Teresa;Saiz-Rodriguez, Miriam;Mejia, Gina;Abad-Santos, Francisco. And the article was included in BMC Pharmacology and Toxicology in 2020.Quality Control of Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide The following contents are mentioned in the article:

We aimed to evaluate the effect of food on the pharmacokinetics of omeprazole, rabeprazole, and pantoprazole. Setting: The study population comprised 186 healthy volunteers participating in 6 bioequivalence clin. trials. Method: Subjects were evaluated to determine the effect of a high-fat breakfast on the pharmacokinetics of omeprazole (n = 36), rabeprazole (n = 69), and pantoprazole (n = 81). Main outcome measure: Drug plasma concentrations were measured using high-performance liquid chromatog. coupled to mass spectrometry. Results: Food affected the pharmacokinetics of omeprazole (increased T_max and decreased AUC and C_max), pantoprazole (increased T_max and decreased AUC), and rabeprazole (increased T_max, C_max and half-life). Food increased variability in T_max for all 3 drugs, delaying absorption around 3 to 4 h and until 20 h in some subjects. Conclusion: As food delays the absorption of PPIs and increases their variability, it would be better to administer these drugs under fasting conditions. Trial registration: European Union Drug Regulating Authorities Clin. Trials Database: EudraCT: 2004-003863-59 (registration date 05/MAR/2004), EudraCT 2006-001162-17 (registration date 17-MAR-2006), EudraCT: 2007-002489-37 (registration date 12-JUN-2007), EudraCT: 2007-002490-31 (registration date 12-JUN-2007), EudraCT: 2010-024029-19 (registration date 23-NOV-2010). This study involved multiple reactions and reactants, such as Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6Quality Control of Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide).

Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6) belongs to imidazole derivatives. 1H-imidazole is an imidazole tautomer which has the migrating hydrogen at position 1. It is a conjugate base of an imidazolium cation. It is a conjugate acid of an imidazolide. It is a tautomer of a 4H-imidazole. Imidazole has been usedin the lysis, wash and elution buffer for the purification of histidine tagged Sonic Hedgehog(shh-N) protein, in elution buffer in stepwise gradient for the purification of histidine tagged aldo keto reductases using nickel affinity chromatography, as a component of homogenization buffer for the purification of phagosomal compartments from dendritic cells.Quality Control of Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Comparative characteristics of proton pump inhibitor effectiveness in the treatment of gastric ulcer and duodenal ulcer was written by Balitska, Olesya P.;Germanyuk, Tamara A.;Hryhoruk, Yuliia M.;Ivko, Tatiana I.;Tomashevska, Yuliia O.;Koval, Vasyl M.;Polishchuk, Yuliia M.;Hutsol, Viktoriia V.;Artemchuk, Myhailo A.. And the article was included in Current Issues in Pharmacy and Medical Sciences in 2020.Synthetic Route of C18H20N3NaO3S The following contents are mentioned in the article:

Materials and methods: The materials of this research are the results of 86 original studies on the effectiveness of proton pump inhibitors anal. Methods. Descriptive, statistical, retrospective. Results and Conclusion. According to the clin. random researches, Omeprazole preparations are not included in the list due to proven better effectiveness of Esomeprazole drugs. Moreover, lansoprazole drugs are not included according to proven short-acid inhibitory effect. In addition, the brand of mentioned above preparation does not exist on the pharmaceutical market of Ukraine. Furthermore, rabeprazole preparations are presented in the research by Pariet (brand) and by the effective generic Barol, while pantoprazole preparations are represented in the research by Kontrolok (brand) and by the generic Pultset, as well as by Nolpaza. Herein, the Pantosan effect was not significantly different from the effect of Pultset and Nolpaza, but the preparation is much more expensive. In terms of efficiency (%), 4 wk repair of mucosal defects was carried out by way of the following treatment regimens: Barol + Amoxicillin + Clarythromycin (90.9卤6.2), Pariet + Amoxicillin + Clarythromycin (83卤2.6), Kontrolok + Amoxicillin + Clarythromycin (100卤1.3), Pultset + Amoxicillin + Clarythromycin (88卤4.1), Nolpaza + Amoxicillin + Clarythromycin (72卤4.1), Ezolonh + Amoxicillin + Clarythromycin (87.7卤3.8), Neksium + Amoxicillin + Clarythromycin (96.1卤3.1). This study involved multiple reactions and reactants, such as Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6Synthetic Route of C18H20N3NaO3S).

Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6) belongs to imidazole derivatives. Many natural products, especially alkaloids, contain the imidazole ring. These imidazoles share the 1,3-C3N2 ring but feature varied substituents. Imidazole also acts as a microtubule destabilizing agents and inhibits topoisomerase and Cytochrome P450 Family 26 Subfamily A Member 1 (CYP26A1) enzymes.Synthetic Route of C18H20N3NaO3S

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

A turn-on luminescent probe for Fe³⁺ and ascorbic acid with logic gate operation based on a zinc(II)-based metal-organic framework was written by Tang, Jing;Feng, Doudou;Yang, Jie;Ma, Xuehui;Wang, Xiao-Qing. And the article was included in New Journal of Chemistry in 2020.SDS of cas: 1374155-84-6 The following contents are mentioned in the article:

A 2D zinc(II)-based metal-organic framework (Zn-MOF) formulated as [Zn(bimpy)(1,4-ndc)]路H₂O (1, bimpy = 3,5-bis(1-imidazolyl)pyridine and 1,4-ndc = 1,4-naphthalenedicarboxylic acid) was synthesized by solvothermal reaction. Complex 1 exhibits high water and pH-independent stability. It can detect Fe³⁺ and ascorbic acid (AA) as a “turn-off” fluorescence probe and a “turn-on” fluorescence probe in aqueous solution with high sensitivity and selectivity, resp. The detection limits of 1 for Fe³⁺ and AA are about 8.82 x 10^-7 M and 6.12 x 10^-7 M, resp. The fluorescence intensity of the Fe³⁺@1 system can be obviously recovered after adding AA due to the reduction of Fe³⁺, which exhibits a fluorescence “turn-on” signal (turn-off-on) for Fe³⁺@1 toward AA with a low detection limit (3.53 x 10^-7 M). Complex 1 still exhibits good detection of Fe³⁺ and AA after washing and using for five cycles. Addnl., two different multi-input mol. logic gates are established. One is used to distinguish the effect of Fe³⁺ and Fe²⁺ on the fluorescence of complex 1, and the other is to further explain the regulation of Fe³⁺ and AA on the fluorescence of complex 1. This work shows that complex 1 is the first MOF-based “turn-on” fluorescent probe for both Fe³⁺ and AA in aqueous solution This study involved multiple reactions and reactants, such as 3,5-Di(1H-imidazol-1-yl)pyridine (cas: 1374155-84-6SDS of cas: 1374155-84-6).

3,5-Di(1H-imidazol-1-yl)pyridine (cas: 1374155-84-6) belongs to imidazole derivatives. Many natural products, especially alkaloids, contain the imidazole ring. These imidazoles share the 1,3-C3N2 ring but feature varied substituents. Imidazole derivatives have antibacterial, antifungal and anticancer functionality. It interacts with DNA and also binds to protein and stops cell division.SDS of cas: 1374155-84-6

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Study Evaluating the Effects of the Proton Pump Inhibitor Rabeprazole and Food on the Pharmacokinetics of Lorlatinib in Healthy Participants was written by Xu, Huiping;O’Gorman, Melissa T.;Nepal, Sunil;James, Lee P.;Ginman, Katherine;Pithavala, Yazdi K.. And the article was included in Clinical Pharmacology in Drug Development in 2021.COA of Formula: C18H20N3NaO3S The following contents are mentioned in the article:

The objectives of this phase 1, open-label crossover study (NCT02569554) in healthy adult participants were to determine (1) the effects of the proton pump inhibitor (PPI) rabeprazole on lorlatinib pharmacokinetics (PK), (2) the effects of a high-fat meal on lorlatinib PK, and (3) the relative bioavailability of an oral solution to tablet formulation of lorlatinib under fasted conditions. Participants were followed on-study for 鈮?0 days after the first dose of lorlatinib. Participants received treatments over 4 periods, with a washout of 鈮?0 days between consecutive lorlatinib doses. Twenty-seven participants were enrolled and received lorlatinib, and all were assessed for PK and safety. Results showed no effect of multiple doses of rabeprazole on the total plasma exposure of a single oral dose of lorlatinib 100-mg tablets. The results also indicated that a high-fat meal had no effect on lorlatinib PK after a single 100-mg oral dose. In addition, the relative bioavailability of lorlatinib oral solution compared with lorlatinib tablets was complete (approx. 108%). The safety profile of lorlatinib was consistent with that reported in previous studies, and most treatment-related adverse events were mild to moderate. These data indicate that lorlatinib can be administered with drugs that modify gastric acid, including PPIs, without restriction. These results also confirm that lorlatinib can be administered regardless of food intake. This study involved multiple reactions and reactants, such as Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6COA of Formula: C18H20N3NaO3S).

Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6) belongs to imidazole derivatives. Many natural products, especially alkaloids, contain the imidazole ring. These imidazoles share the 1,3-C3N2 ring but feature varied substituents. Imidazole based anticancer drug find applications in cancer chemotherapy. It is used as buffer component for purification of the histidine tagged recombinant proteins in immobilized metal-affinity chromatography (IMAC).COA of Formula: C18H20N3NaO3S

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

The molecular rationale for the combination of polatuzumab vedotin plus rituximab in diffuse large B-cell lymphoma was written by Kawasaki, Natsumi;Nishito, Yukari;Yoshimura, Yasushi;Yoshiura, Shigeki. And the article was included in British Journal of Haematology in 2022.Reference of 16506-27-7 The following contents are mentioned in the article:

Polatuzumab vedotin (Pola) is an antibody-drug conjugate that targets the B-cell antigen CD79b and delivers monomethyl auristatin E (MMAE). It is approved in combination with bendamustine and rituximab (Rit) for relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL). Understanding the mol. basis of Pola combination therapy with Rit, the key component for the treatment of DLBCL, is important to establish the effective treatment strategies against r/r DLBCL. Here, we examined the rationale for the combination of Pola with Rit using Pola-refractory cells. We found that treatment with Pola increased CD20 expression and sensitivity to Rit-induced complement-dependent cytotoxicity (CDC) in several Pola-refractory cells. Pola treatment increased phosphorylation of AKT and ERK and both AKT- and MEK-specific inhibitors attenuated the Pola-induced increase of CD20 and CDC sensitivity, suggesting that these phosphorylation events were required for this combination efficacy. It was revealed that anti-CD79b antibody increased the phosphorylation of AKT but inhibited the phosphorylation of ERK. In contrast, MMAE potentiated phosphorylation of ERK but slightly attenuated the phosphorylation of AKT. Pola also increased CD20 expression on Pola-refractory xenografted tumors and significantly enhanced antitumor activity in combination with Rit. In conclusion, these results could provide a novel rationale for the combination of Pola plus Rit. This study involved multiple reactions and reactants, such as 4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7Reference of 16506-27-7).

4-(5-(Bis(2-chloroethyl)amino)-1-methyl-1H-benzo[d]imidazol-2-yl)butanoic acid (cas: 16506-27-7) belongs to imidazole derivatives. Many natural products, especially alkaloids, contain the imidazole ring. These imidazoles share the 1,3-C3N2 ring but feature varied substituents. Imidazole is incorporated into many important biological compounds. The most pervasive is the amino acid histidine, which has an imidazole side-chain. Histidine is present in many proteins and enzymes, e.g. by binding metal cofactors, as seen in hemoglobin.Reference of 16506-27-7

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Camostat Mesilate, Pancrelipase, and Rabeprazole Combination Therapy Improves Epigastric Pain in Early Chronic Pancreatitis and Functional Dyspepsia with Pancreatic Enzyme Abnormalities was written by Yamawaki, Hiroshi;Futagami, Seiji;Kaneko, Keiko;Agawa, Shuhei;Higuchi, Kazutoshi;Murakami, Makoto;Wakabayashi, Mako;Sakasegawa, Noriko;Kodaka, Yasuhiro;Ueki, Nobue;Gudis, Katya;Kawamoto, Chiaki;Iwakiri, Katsuhiko. And the article was included in Digestion in 2019.Application of 117976-90-6 The following contents are mentioned in the article:

Background/Aims: The aims of the study are to clarify the pathophysiol. differences among early chronic pancreatitis (ECP), functional dyspepsia with pancreatic (FD-P) enzyme abnormalities and FD patients and to determine whether camostat mesilate, pancrelipase, and rabeprazole triple therapy improve FD symptoms in the ECP patients and FD-P patients in cross-over way. Methods: We enrolled 84 consecutive patients presenting with typical symptoms of FD patients (n = 42), ECP patients (n = 15), and FD-P patients (n = 27). Gastric emptying was assessed by the ¹³C-acetate breath test. ECP was diagnosed based on the criteria recommended by the Japan Pancreatic Association Results: The proportions of female in ECP patients and FD-P were significantly higher compared to that in FD patients. The early phase of gastric emptying in ECP and FD-P patients was significantly disturbed compared to that in FD patients. The primary outcome of this study is that 4 wk of camostat mesilate, pancrelipase, and rabeprazole triple therapy significantly ameliorated epigastric pain in ECP patients compared to acotiamide and rabeprazole combination therapy. Conclusion: Although there were no significant differences in pathophysiol. between ECP patients and FD-P patients, triple therapy can significantly ameliorate epigastric pain in ECP patients. Further studies will be needed to clarify why triple therapy can improve epigastric pain in ECP patients. This study involved multiple reactions and reactants, such as Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6Application of 117976-90-6).

Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6) belongs to imidazole derivatives. Many natural products, especially alkaloids, contain the imidazole ring. These imidazoles share the 1,3-C3N2 ring but feature varied substituents. Imidazole also acts as a microtubule destabilizing agents and inhibits topoisomerase and Cytochrome P450 Family 26 Subfamily A Member 1 (CYP26A1) enzymes.Application of 117976-90-6

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Does Rabeprazole Sodium Alleviate the Anti-diabetic Activity of Linagliptin Drug-Drug Interaction Analysis by In vitro and In vivo Methods was written by Hossain, Jamal Md.;Sultan, Zakir Md.;Rashid, Mohammad A.;Kuddus, Ruhul Md.. And the article was included in Drug Research (Stuttgart, Germany) in 2020.Synthetic Route of C18H20N3NaO3S The following contents are mentioned in the article:

Drug interaction has turned into the preeminent regarding issues for a prescriber during polypharmacy. The foremost objective of this research was to form a complex between linagliptin and rabeprazole sodium by in vitro interactions. The interactions between the drugs have been examined by monitoring some chromatog. and spectroscopic analyses viz. TLC, HPLC, FT IR, UV, Job’s plot, conductometric titrations, and Ardon’s spectrophotometric strategy. Rabeprazole sodium formed a stable complex with linagliptin, which was ensured from the insight of these anal. data. The retention time (R _t) of the formed complex was 5.303 min, where the R _twere 3.364 and 3.103 min for linagliptin and rabeprazole sodium, resp., in HPLC chromatograms. In FT IR and UV spectra of the formed complex revealed some disappearance of characteristic peaks that affirmed the complexation. All of the variations of the spectrophotometric and chromatog. properties from the antecedent drugs indicated the drug drug interaction. The assessment of anti diabetic property on alloxan induced Swiss albino mice proved significant in vivointeraction between the drugs. Animal study that the hypoglycemic activity of linagliptin might be significantly affected due to the complex formation of the drug with a proton pump inhibitor (PPI). It is the primary outcome of the interaction, which recommends the bigger in vivostudy or clin. monitoring on the human model. This study involved multiple reactions and reactants, such as Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6Synthetic Route of C18H20N3NaO3S).

Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6) belongs to imidazole derivatives. Imidazole derivatives generally have good solubility in protic solvents. Simple imidazole derivatives, such as 1H-imidazole, 2-methyl-1H-imidazole, and 1,2-dimethylimidazole, have very high solubility in water. Imidazole derivatives have antibacterial, antifungal and anticancer functionality. It interacts with DNA and also binds to protein and stops cell division.Synthetic Route of C18H20N3NaO3S

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Comparative Study on Effect of Rabeprazole Versus Omeprazole in Acid-peptic Disorder with Helicobacter pylori Infection. was written by Gurung, Sukh Bahadur;Kc, Shiva Raj;Gyawali, Purnima;Amatya, Gyanendra Lal. And the article was included in Journal of Nepal Health Research Council in 2020.Synthetic Route of C18H20N3NaO3S The following contents are mentioned in the article:

BACKGROUND: Gastritis is one of the common diseases, which is frequently caused by Helicobacter pylori. Triple therapy has resulted significant decrease in morbidity and complications. Newer proton pump inhibitor drug rabeprazole has been introduced in the market. The aim of this study is to compare its efficacy with omeprazole in triple therapy regimen. METHODS: A total of 100 patients who were positive for Helicobacter pylori and gave consent in participating in the study were included. Fifty patients were prescribed omeprazole-based triple therapy and other 50 were prescribed with rabeprazole-based triple therapy. After 2 weeks of triple therapy and 4 weeks of proton pump inhibitor treatment, Helicobacter pylori antigen was tested in faecal material. RESULTS: Out of 100 patients, there was significant correlation between epigastric pain, nausea and water brash with p value, 0.001. Similarly P-value was < 0.001 among hiatus hernia and reflux whereas p value was < 0.05 between bile reflux, hiatus hernia and reflux. In follow up study, after triple therapy, Helicobacter pylori antigen tests were negative in 94% of the study population, who were prescribed rabeprazole which was similar who were prescribed omeprazole (92%). CONCLUSIONS: Rabeprazole (20 mg) has proved similar Helicobacter pylori eradication rates compared with omeprazole (40 mg) when co-administered with of antibiotics (amoxicillin and clarithromycin) for two weeks. This study involved multiple reactions and reactants, such as Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6Synthetic Route of C18H20N3NaO3S).

Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6) belongs to imidazole derivatives. Imidazole is a heterocyclic compound with a five-membered planar ring. It is amphoteric and highly polar. Imidazole also acts as a microtubule destabilizing agents and inhibits topoisomerase and Cytochrome P450 Family 26 Subfamily A Member 1 (CYP26A1) enzymes.Synthetic Route of C18H20N3NaO3S

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Multilevel Approach for the Treatment of Giardiasis by Targeting Arginine Deiminase was written by Fernandez-Lainez, Cynthia;de la Mora-de la Mora, Ignacio;Garcia-Torres, Itzhel;Enriquez-Flores, Sergio;Flores-Lopez, Luis A.;Gutierrez-Castrellon, Pedro;Yepez-Mulia, Lilian;Matadamas-Martinez, Felix;de Vos, Paul;Lopez-Velazquez, Gabriel. And the article was included in International Journal of Molecular Sciences in 2021.Application In Synthesis of Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide The following contents are mentioned in the article:

Giardiasis represents a latent problem in public health due to the exceptionally pathogenic strategies of the parasite Giardia lamblia for evading the human immune system. Strains resistant to first-line drugs are also a challenge. Therefore, new antigiardial therapies are urgently needed. Here, we tested giardial arginine deiminase (GlADI) as a target against giardiasis. GlADI belongs to an essential pathway in Giardia for the synthesis of ATP, which is absent in humans. In silico docking with six thiol-reactive compounds was performed; four of which are approved drugs for humans. Recombinant GlADI was used in enzyme inhibition assays, and computational in silico predictions and spectroscopic studies were applied to follow the enzyme’s structural disturbance and identify possible effective drugs. Inhibition by modification of cysteines was corroborated using Ellman’s method. The efficacy of these drugs on parasite viability was assayed on Giardia trophozoites, along with the inhibition of the endogenous GlADI. The most potent drug against GlADI was assayed on Giardia encystment. The tested drugs inhibited the recombinant GlADI by modifying its cysteines and, potentially, by altering its 3D structure. Only rabeprazole and omeprazole decreased trophozoite survival by inhibiting endogenous GlADI, while rabeprazole also decreased the Giardia encystment rate. These findings demonstrate the potential of GlADI as a target against giardiasis. This study involved multiple reactions and reactants, such as Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6Application In Synthesis of Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide).

Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6) belongs to imidazole derivatives. Many natural products, especially alkaloids, contain the imidazole ring. These imidazoles share the 1,3-C3N2 ring but feature varied substituents. Imidazole based anticancer drug find applications in cancer chemotherapy. It is used as buffer component for purification of the histidine tagged recombinant proteins in immobilized metal-affinity chromatography (IMAC).Application In Synthesis of Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem

Clinical study of bifidobacteria triple viable bacteria capsule combined with quadruple therapy in treatment of HP positive gastric ulcer was written by Li, Huan-qun. And the article was included in Xiandai Zhenduan Yu Zhiliao in 2021.Recommanded Product: 117976-90-6 The following contents are mentioned in the article:

Objective: To investigate the therapeutic effect of Bifidobacterium triple viable bacteria capsule combined with quadruple therapy on Helicobacter pylori (HP) pos. gastric ulcer (SU). Methods: A total of 50 HP-pos. SU patients admitted to our hospital from Jan. 2019 to Oct. 2020 were selected and divided into the control group and the observation group with 25 cases in each group by tossing a coin method. The control group was given quadruple therapy, and the observation group was given Bifidobacterium triple viable capsules orally on the basis of the control group. The curative effect, HP neg. rate and adverse reactions were compared between the two groups. Results: After treatment, the total effective rate of the observation group was significantly higher than that of the control group, and the difference was statistically significant (P<0.05). After treatment, 44 cases of HP in the observation group turned neg., and the neg. conversion rate was 89.80%. In the control group, HP turned neg. in 33 cases, and the neg. conversion rate was 68.75%. There was a statistically significant difference between the two groups (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion: Bifidobacterium triple viable bacteria capsule combined with quadruple therapy is effective in the treatment of HP pos. SU, which can improve the HP neg. conversion rate and has good safety. This study involved multiple reactions and reactants, such as Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6Recommanded Product: 117976-90-6).

Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide (cas: 117976-90-6) belongs to imidazole derivatives. Many natural products, especially alkaloids, contain the imidazole ring. These imidazoles share the 1,3-C3N2 ring but feature varied substituents. Imidazole also acts as a microtubule destabilizing agents and inhibits topoisomerase and Cytochrome P450 Family 26 Subfamily A Member 1 (CYP26A1) enzymes.Recommanded Product: 117976-90-6

Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem